Salt AI Raises $10M to Advance Contextual AI in Life Sciences

Salt AI, a Los Angeles-based company specializing in contextual AI for enterprise applications in the life sciences and health technology sectors, has secured $10 million in a new funding round. The investment was led by Morpheus Ventures, with additional participation from Struck Capital, Marbruck Investments, and CoreWeave. The capital will be used to accelerate Salt AI’s growth by expanding its customer base among top-tier biopharmaceutical and healthcare organizations actively investing in advanced AI innovation. The company also plans to scale its global AI engineering teams to strengthen product development and support growing demand. Salt AI’s platform focuses on delivering context-aware AI solutions tailored to the complex data environments of life sciences and healthcare. Unlike general-purpose AI tools, Salt AI’s technology is designed to understand and operate within the specific workflows, terminologies, and regulatory requirements of medical research, drug discovery, clinical trials, and patient care. By embedding AI deeply into enterprise systems, the company enables faster, more accurate decision-making across research, development, and operational functions. The new funding comes at a pivotal moment as AI adoption in healthcare and biopharma accelerates. Pharmaceutical companies are increasingly turning to AI to streamline drug discovery, analyze vast biological datasets, predict clinical outcomes, and improve patient stratification. Salt AI positions itself as a key enabler of this transformation by offering AI that doesn’t just process data but understands context—such as the nuances of medical terminology, regulatory standards, and scientific literature—leading to more reliable and actionable insights. The backing from Morpheus Ventures, known for its focus on high-impact technology ventures, signals strong confidence in Salt AI’s mission and market potential. Struck Capital, Marbruck Investments, and CoreWeave, a leader in AI infrastructure, bring not only financial support but also strategic value. CoreWeave’s expertise in scalable cloud computing and AI workloads will likely enhance Salt AI’s ability to deliver high-performance, secure AI services to enterprise clients. With the new capital, Salt AI intends to deepen its partnerships with major biopharma firms and healthcare providers, helping them integrate contextual AI into their core operations. The company will also invest in expanding its engineering talent globally, particularly in AI research, natural language processing, and machine learning systems, to maintain a competitive edge in a rapidly evolving field. The funding round underscores growing investor interest in AI applications that solve real-world problems in regulated, high-stakes industries. As AI becomes central to innovation in healthcare, companies like Salt AI are bridging the gap between cutting-edge technology and practical, compliant enterprise use. Salt AI’s success reflects a broader trend: AI is no longer just a tool for tech giants but a mission-critical asset for industries where precision, trust, and regulatory compliance are paramount. By focusing on context, accuracy, and domain-specific intelligence, Salt AI is helping life sciences and health tech organizations unlock new levels of efficiency and insight. The company’s vision is to become the standard for contextual AI in enterprise healthcare, enabling faster breakthroughs in drug development, improved clinical outcomes, and more personalized patient care. With this new round of funding, Salt AI is poised to expand its impact and solidify its role as a leader in the next generation of AI-driven healthcare innovation.